In vivo response of EpCAM+ pancreatic cancer cells to gemcitabine plus anti-LIF neutralizing antibody treatment

ABSTRACT: The goal of this study is to investigate the molecular mechanisms of LIF action on pancreatic cancer cells in the classical pancreatic ductal adenocarcinoma mouse model KrasLSL-G12D;Tp53f/f;Rosa26LSL-Luc;Pdx1-Cre mice EpCAM+ pancreatic cancer cells were isolated from pancreatic tumors developped in KrasLSL-G12D;Tp53f/f;Rosa26LSL-Luc;Pdx1-Cre mice treated with either gemcitabine plus control IgG or gemcitabine plus anti-LIF antibody by FACS

ORGANISM(S): Mus musculus

PROVIDER: GSE99187 | GEO | 2018/12/21

REPOSITORIES: GEO